08:46 AM EST, 11/13/2024 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) , which lost 15% on the Toronto Stock Exchange on Tuesday, on Wednesday said it will present pre-clinical data on MDNA11 and IL-2 Superkines in glioblastoma models at the 29th Annual Meeting of the Society of Neuro-Oncology (SNO) in Houston at the end of the month.

The company will also present pre-clinical data in aggressive metastatic models of breast cancer incorporating MDNA11 pre-treatment prior to surgery (neoadjuvant) at the 2024 San Antonio Breast Cancer Symposium (SABCS) next month.